Activist hedge funds are partnering with institutional investors to an unprecedented degree and “no company can consider itself immune,” opined lawyer Martin Lipton, a well-known corporate advocate who operates primarily at odds with activist hedge funds. The creator of the corporate “poison pill” defense against activist overtures outlined the situation with activists and revealed how corporations might want to consider handling the challenge. [munger] No corporation is immune from an activist challenge, and successful firms offer less risk “No company is too large, too popular or too successful,” Lipton noted in a recent blog post on the Harvard Law Forum on…
Marty Lipton Warns Corporations To Prepare For Activist Onslaught; No One Is "Immune"
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.